Entries by Thomas Gabrielczyk

Analytical demand of CRISPR gene therapies

Gene Editing?CRISPR-Cas9 gene editing offers substantial improvements over previous gene editing technologies in terms of ease of use, speed, efficacy, and cost. Not surprisingly, CRISPR-Cas9 editing has taken biomedical science by storm. While the technology is relatively simple in handling at the level of basic research, the use of CRISPR genome editing in therapeutical applications poses a bunch of
analytical challenges.

Medical cold chain for gene and cell therapies

The medical cold chain is the network of refrigerators, freezers, and transport solutions tasked to always keep samples and specimens at their intended temperatures. When it comes to cell and gene research and therapy, temperature requirements can be demanding, requiring the deployment of specialised refrigeration products. With its refrigeration solutions, B Medical Systems can help in always keeping your specimens safe.

Thermo Scientific HyPeak Single-Use Chromatography System

The HyPeak Chromatography System provides a complete, single-use solution for chromatographic purificationa principal unit operation in downstream bioprocessing of recombinant proteins such as monocolonal antibodies and viral vector production. Pre-engineered system options and modular-flow kit designs allow for selection of tools and technology suitable for a broad range of applications. The HyPeak Chromatography System can be used for multiple chromatography steps and, combined with the automation package, provides the platform necessary for consistent, high-performing purification

Success together with CDMOs

When the time comes for a biopharma company to outsource its production, or to get support for the development of a new project, the pool of available CDMOs is quite deep. Everyone knows the big players, but maybe they are not suitable for everyone. They have proven expertise but as it happens with big organisations, they are usually not very flexible with increased indirect costs.

Curevac withdraws MAA of CVnCoV

German CureVac N.V. has withdrawn its application for market approval of its COVID-19 vaccine candidate and will focus on the development of a second-generation vaccine.